只会往差了改。还抱有_老虎社区_美港股上老虎

只会往差了改。还抱有幻想那😂

港股异动 | CRO概念股涨幅扩大药明康德(02359)一度升12% 传美国立法者考虑对生物安全法案进行更改

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":378565432684984,"tweetId":"378565432684984","gmtCreate":1733465932853,"gmtModify":1733465935921,"author":{"id":4160227637143462,"idStr":"4160227637143462","authorId":4160227637143462,"authorIdStr":"4160227637143462","name":"Blackland","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>只会往差了改。还抱有幻想那😂</p></body></html>","htmlText":"<html><head></head><body><p>只会往差了改。还抱有幻想那😂</p></body></html>","text":"只会往差了改。还抱有幻想那😂","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/378565432684984","repostId":2489473117,"repostType":2,"repost":{"id":"2489473117","kind":"news","pubTimestamp":1733463302,"share":"https://www.laohu8.com/m/news/2489473117?lang=&edition=full","pubTime":"2024-12-06 13:35","market":"us","language":"zh","title":"港股异动 | CRO概念股涨幅扩大 药明康德(02359)一度升12% 传美国立法者考虑对生物安全法案进行更改","url":"https://stock-news.laohu8.com/highlight/detail?id=2489473117","media":"智通财经","summary":"智通财经APP获悉，CRO概念股涨幅进一步扩大，截至发稿，药明康德涨10%，报55港元；康龙化成涨8.12%，报14.64港元；药明生物涨7.02%，报17.6港元；昭衍新药涨5.62%，报9.4港元。消息面上，市场消息称，美国立法者正考虑对法案进行更改，妥协版本内容包括增加对相关公司行政审查环节，而非自动禁止生物制药公司与中国公司合作。这些潜在的修订涉及立法中专门点名中国公司的关键部分。","content":"<html><body><p>智通财经APP获悉，CRO概念股涨幅进一步扩大，截至发稿，<a href=\"https://laohu8.com/S/603259\">药明康德</a>(02359)涨10%，报55港元；<a href=\"https://laohu8.com/S/300759\">康龙化成</a>(03759)涨8.12%，报14.64港元；<a href=\"https://laohu8.com/S/02269\">药明生物</a>(02269)涨7.02%，报17.6港元；<a href=\"https://laohu8.com/S/603127\">昭衍新药</a>(06127)涨5.62%，报9.4港元。</p><p>消息面上，市场消息称，美国立法者正考虑对法案进行更改，妥协版本内容包括增加对相关公司行政审查环节，而非自动禁止生物制药公司与中国公司合作。这些潜在的修订涉及立法中专门点名中国公司的关键部分。</p><p>民生证券近期研报指出，关注2024年12月参议院日程及排期，单独立法方面H.R.8333相关进展；美联储降息50bp，biotech融资端有望延续上半年改善趋势，以海外客户为主要订单和收入贡献的CXO龙头有望进一步回暖。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | CRO概念股涨幅扩大 药明康德(02359)一度升12% 传美国立法者考虑对生物安全法案进行更改</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | CRO概念股涨幅扩大 药明康德(02359)一度升12% 传美国立法者考虑对生物安全法案进行更改\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-06 13:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1221277.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，CRO概念股涨幅进一步扩大，截至发稿，药明康德(02359)涨10%，报55港元；康龙化成(03759)涨8.12%，报14.64港元；药明生物(02269)涨7.02%，报17.6港元；昭衍新药(06127)涨5.62%，报9.4港元。消息面上，市场消息称，美国立法者正考虑对法案进行更改，妥协版本内容包括增加对相关公司行政审查环节，而非自动禁止生物制药公司与中国公司合作。这些...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1221277.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"603259":"药明康德","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU1720050803.USD":"安联全方位中国股票基金","LU1997245177.USD":"安联神洲A股基金","BK1583":"高瓴概念","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0823426308.USD":"法巴中国股票基金","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0051755006.USD":"摩根大通中国A (dist)","LU1688375341.USD":"贝莱德中国灵活股票基金","BK0216":"研究试验","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK1610":"ETF&股票定投概念","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","06127":"昭衍新药","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","02359":"药明康德","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","02269":"药明生物","03759":"康龙化成","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1589":"北水核心资产","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC"},"source_url":"http://www.zhitongcaijing.com/content/detail/1221277.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2489473117","content_text":"智通财经APP获悉，CRO概念股涨幅进一步扩大，截至发稿，药明康德(02359)涨10%，报55港元；康龙化成(03759)涨8.12%，报14.64港元；药明生物(02269)涨7.02%，报17.6港元；昭衍新药(06127)涨5.62%，报9.4港元。消息面上，市场消息称，美国立法者正考虑对法案进行更改，妥协版本内容包括增加对相关公司行政审查环节，而非自动禁止生物制药公司与中国公司合作。这些潜在的修订涉及立法中专门点名中国公司的关键部分。民生证券近期研报指出，关注2024年12月参议院日程及排期，单独立法方面H.R.8333相关进展；美联储降息50bp，biotech融资端有望延续上半年改善趋势，以海外客户为主要订单和收入贡献的CXO龙头有望进一步回暖。","news_type":1},"isVote":1,"tweetType":1,"viewCount":67,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/378565432684984"}